Advances in Cancer Biology-Metastasis
Advances in Cancer Biology - Metastasis is a gold open access journal from Elsevier devoted to basic and translational research on metastatic cancer, launched in 2021, and its 2025 Journal Impact Factor is 4.2《癌症生物学进展-转移》（Advances in Cancer Biology - Metastasis）是（Elsevier）出版的金色开放获取期刊，专注转移性癌症的基础与转化研究，于 2021 年创办，2025 年期刊影响因子为 4.2。
Scope
- The journal addresses the unresolved problem of cancer metastasis该刊关注尚未解决的癌症转移难题。
- It publishes preclinical findings that could inform clinical practice against metastatic disease该刊发表可能指导转移性疾病临床实践的临床前发现。
- Diagnostic tools for the detection of metastasis are within scope转移检测的诊断工具在其征稿范围内。
- Translational research on metastatic disease is central to the journal转移性疾病的转化研究是该刊的核心。
- Therapeutic approaches to combat metastatic progression are covered对抗转移进展的治疗策略亦在其范围内。
- It accepts reviews, research articles, mini-reviews and technical papers该刊接受综述、研究论文、小型综述与技术论文。
History
- The journal was launched in 2021 by Elsevier该刊由（Elsevier）于 2021 年创办。
- It is a peer-reviewed open access journal with no subscription charges该刊是同行评审的开放获取期刊，不收取订阅费。
- An article publishing charge supports immediate free access to all articles文章处理费支撑所有文章即时免费开放。
- More clinically oriented papers are accepted when tied to molecular features of tumours当论文与肿瘤的分子特征相关联时，偏临床的投稿亦被接受。
- It is indexed in the Emerging Sources Citation Index and Scopus该刊被新兴来源引文索引与（Scopus）收录。
- Its 2025 Journal Impact Factor is 4.2, up from 3.0 in 2024该刊 2025 年影响因子为 4.2，高于 2024 年的 3.0。
Editors
- The Editor-in-Chief is Ira-Ida Skvortsova, who is based in Austria现任主编为（Ira-Ida Skvortsova），常驻奥地利。
- She works on translational oncology and radiation research她从事转化肿瘤学与放射研究。
- The editorial office is managed by Carly Middendorp编辑部由（Carly Middendorp）负责。
- An international board of editors handles manuscripts across metastasis research国际化的编辑委员会处理转移研究各方向的稿件。
- Thematic issues are organized around focused topics of metastatic disease专题刊围绕转移性疾病的特定方向组织。
- Manuscripts are assessed through external peer review稿件经外部同行评审予以评估。